Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer - Takeaways - MDSpire

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

  • October 8, 2025

  • 3 min

Share

  • 1

    Molecular testing is crucial for accurately diagnosing mucinous tubular and spindle cell carcinoma (MTSCC) and papillary renal cell carcinoma (PRCC).

  • 2

    MTSCC is a rare kidney cancer subtype characterized by tubules, spindle cells, and mucinous connective tissue.

  • 3

    Papillary formations, previously a marker for PRCC, were found in all five MTSCC cases studied, complicating diagnosis.

  • 4

    The research team compared MTSCC cases with papillary formation to PRCC cases and performed chromosomal analysis for confirmation.

  • 5

    Accurate diagnosis through molecular testing can lead to better treatment plans for patients with kidney cancer.

Original Source(s)

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

  • October 8, 2025

Related Content

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

Rethinking the evidence for intensive surveillance after renal tumor ablation

Enhanced recovery after surgery nursing improves postoperative outcomes in laparoscopic radical nephrectomy: a cumulative meta-analysis